Prevagen contains apoaequorin, a protein from jellyfish, marketed as a memory aid for age-related cognitive decline. Its claims have failed legal and scientific scrutiny—the main clinical trial found no benefit, and in December 2024 a federal court ordered the maker to stop claiming memory improvement due to lack of scientific support. Reading Prevagen claims accurately means understanding how the evidence was tested, what the courts found, and what the biology actually shows. This article walks you through the clinical data, regulatory findings, and how to spot unreliable supplement marketing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Prevagen Is and Claims to Do
- What the Clinical Evidence Actually Shows
- Legal and Regulatory Findings
- Why the Biology Doesn't Support the Claims
- How to Read Memory Supplement Claims
- Frequently Asked Questions
What Prevagen Is and Claims to Do
Prevagen is a dietary supplement containing apoaequorin, a protein synthesized from the bioluminescent jellyfish *Aequorea victoria*, marketed to support memory and brain health in older adults. The manufacturer claimed the supplement improves memory within 90 days and is "clinically proven." As a dietary supplement, Prevagen does not require FDA approval before sale—the FDA does not review dietary supplements for safety or efficacy beforehand, only after they reach consumers.
However, manufacturers must still substantiate any specific health claims they advertise. This means Prevagen entered the market without proof of effectiveness, but the company remained legally required to back up its marketing claims.
What the Clinical Evidence Actually Shows
The main trial supporting Prevagen was the Madison Memory Study, a manufacturer-funded trial of 218 older adults over 90 days. In its primary analysis, the study found no statistically significant difference between Prevagen and placebo; positive results appeared only after researchers examined dozens of data subsets in what is called "subgroup analysis"—a method unreliable for establishing drug efficacy. This is a critical red flag when reading supplement claims.
Searching through many data slices until favorable results emerge creates an illusion of benefit where the main study found none. Two of the three other clinical studies Prevagen cites were never published in peer-reviewed journals, which prevents independent scientists from verifying the methods and results. Almost no independent research confirms Prevagen's claims—clinical evidence comes almost exclusively from small, company-funded trials without replication by external researchers.
Legal and Regulatory Findings
In 2017, the Federal Trade Commission and New York State accused Quincy Bioscience of false advertising. They alleged the company claimed memory improvement within 90 days and provided "clinical proof" without adequate support, relying on the Madison study that actually showed no significant cognitive benefit.
After years of litigation, the courts sided with regulators. A federal judge in December 2024 ordered Quincy Bioscience to cease claiming that Prevagen improves memory or cognition, produces results within 90 days, or is "clinically proven". Additionally, in 2020 the company agreed to refund consumers up to $2.5 million in a class-action settlement over deceptive advertising claims, though it did not admit wrongdoing.
Why the Biology Doesn't Support the Claims
For apoaequorin to improve memory, it must reach the brain and alter cognition. This encounters two insurmountable barriers. Apoaequorin is a protein that is rapidly digested in the stomach and broken down into amino acids and small peptides, like any other dietary protein—it does not survive intact to be absorbed into the bloodstream.
No evidence shows the jellyfish protein can cross the blood-brain barrier, the selective shield protecting the brain from most large molecules. Scientific consensus, including reviews by the Merck Manual, concludes there are no high-quality studies demonstrating apoaequorin is effective for memory loss or any other health condition. This assessment reflects decades of research into how supplements affect the brain.
How to Read Memory Supplement Claims
When you encounter marketing for any memory supplement, evaluate it with these questions: The 2024 court order now legally restricts Prevagen's advertising, so any marketing claims about memory improvement you find online or in older materials are violations of that injunction.
- Is the claim backed by independent research, or only company-funded studies?
- Does the evidence come from a large, peer-reviewed published trial, or from unpublished or subgroup analyses?
- Does the company claim specific short-term results—like 90-day improvement? This often masks studies that found no overall benefit.
- Has the company faced legal action? Search the name plus "FTC" or "lawsuit" to find official findings.
- Does it claim to cure, treat, or prevent disease without FDA approval? That is a warning sign.
Frequently Asked Questions
If Prevagen doesn't work, why is it still sold?
Dietary supplements do not require FDA approval before sale. While the 2024 court order restricts the company's advertising claims, it does not remove the product from shelves—the restriction applies to marketing statements, not availability.
Should someone stop taking Prevagen if they're already using it?
Since the clinical evidence shows no cognitive benefit and the supplement cannot biologically reach the brain as claimed, continued use will not improve memory. Discuss with your doctor whether to continue, especially if cost or health interactions are concerns, and consider evidence-based memory supports like cognitive exercise, physical activity, sleep, and social engagement instead.
